Fig. 5

Stromal TINAGL1 expression is significantly correlated with the oncologic outcomes in DGC patients. A Representative western blotting image of TINAGL1 expression in paired normal and tumor tissues (n = 17). The graph indicates the relative TINAGL1 expression to GAPDH. Data were analyzed using a paired t-test. B TINAGL1 expression in normal and diffuse-type tumor tissues from the TCGA-STAD dataset. Data were analyzed using the Wilcoxon test. C Representative images and graph of RNA-ISH in paired normal tumor tissues (n = 20; red, TINAGL1; green, COL1A1; scale bars, 50 μm). Data were analyzed using a paired t-test. D Arrows indicate red dots in COL1A1-positive cells (scale bar, 20 μm). E Graph indicates stromal TINAGL1 expression of DGC patient tumor tissues using RNA-ISH and expression according to resection, stage, and lymph node metastasis status (n = 32). Data were analyzed using the Wilcoxon test. F Kaplan–Meier plot for stromal TINAGL1 expression in DGC patients (n = 32). G Kaplan–Meier plots for TINAGL1 and COL1A1, ACTA2, or FAP expression in DGC patients from the GSE15459 dataset (n = 75). *P < 0.05, **P < 0.01, ****P < 0.0001